Efficacy and Safety of New Adjuvants

Aucouturier, J.; Ganne, V.; Laval, A.

doi:10.1111/j.1749-6632.2000.tb05343.x

Cited by 22 publications

(15 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Montanide ISA 51 is a water-in-oil emulsion developed by SEPPIC (Paris, France), containing the naturally metabolizable oil Drakeol 6 VR and mannide mono-oleate as emulsifier, and the adjuvant promotes antibody formation and significant cytotoxic T-cell activity [23], [24]. Montanide IMS 4112 VG PR, (one of the Montanide IMS group of adjuvants from SEPPIC), is a water-dispersible composition containing (undisclosed) immuno-stimulatory organic compounds and excipient [25].…”

Section: Methodsmentioning

confidence: 99%

Generation of Humoral Immune Responses to Multi-Allele PfAMA1 Vaccines; Effect of Adjuvant and Number of Component Alleles on the Breadth of Response

et al. 2010

View full text Add to dashboard Cite

There is increasing interest in multi-allele vaccines to overcome strain-specificity against polymorphic vaccine targets such as Apical Membrane Antigen 1 (AMA1). These have been shown to induce broad inhibitory antibodies in vitro and formed the basis for the design of three Diversity-Covering (DiCo) proteins with similar immunological effects. The antibodies produced are to epitopes that are shared between vaccine alleles and theoretically, increasing the number of component AMA1 alleles is expected to broaden the antibody response. A plateau effect could however impose a limit on the number of alleles needed to achieve the broadest specificity. Moreover, production cost and the vaccine formulation process would limit the number of component alleles. In this paper, we compare rabbit antibody responses elicited with multi-allele vaccines incorporating seven (three DiCos and four natural AMA1 alleles) and three (DiCo mix) antigens for gains in broadened specificity. We also investigate the effect of three adjuvant platforms on antigen specificity and antibody functionality. Our data confirms a broadened response after immunisation with DiCo mix in all three adjuvants. Higher antibody titres were elicited with either CoVaccine HT™ or Montanide ISA 51, resulting in similar in vitro inhibition (65–82%) of five out of six culture-adapted P. falciparum strains. The antigen binding specificities of elicited antibodies were also similar and independent of the adjuvant used or the number of vaccine component alleles. Thus neither the four extra antigens nor adjuvant had any observable benefits with respect to specificity broadening, although adjuvant choice influenced the absolute antibody levels and thus the extent of parasite inhibition. Our data confirms the feasibility and potential of multi-allele PfAMA1 formulations, and highlights the need for adjuvants with improved antibody potentiation properties for AMA1-based vaccines.

show abstract

Section: Methodsmentioning

confidence: 99%

Generation of Humoral Immune Responses to Multi-Allele PfAMA1 Vaccines; Effect of Adjuvant and Number of Component Alleles on the Breadth of Response

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Each monkey was immunized on week 16 with 100 μg of FI-RhCMV in the presence of the water-in-oil Montanide ISA 720 adjuvant (Seppic Inc., Fairfield, NJ) [17,18]. FI-RhCMV was diluted with protein (in PBS) and repeatedly mixed through two syringes connected by a 20-gauge needle with ISA 720 at a ratio of 3:7 (protein:adjuvant) to achieve full emulsification.…”

Section: Methodsmentioning

confidence: 99%

“…This study was initiated to determine whether a combination prime/boost strategy is applicable to CMV in a nonhuman primate setting. Building upon our prior study involving DNA immunization in rhesus macaques [16] and that of Morello et al with MCMV [9], seronegative rhesus macaques were first immunized with plasmid expression vectors for RhCMV pp65-2, gB, and IE1 and then boosted with FI-RhCMV virions formulated in the water-in-oil adjuvant Montanide ISA 720 [17,18]. …”

Section: Introductionmentioning

confidence: 99%

A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus

Abel

Strelow

Yue

et al. 2008

Vaccine

View full text Add to dashboard Cite

A previous study in nonhuman primates demonstrated that genetic immunization against the rhesus cytomegalovirus phosphoprotein 65-2 (pp65-2) and glycoprotein B (gB) antigens both stimulated antigen-specific antibodies and CD8 T cell responses, and significantly reduced plasma viral loads following intravenous challenge with RhCMV. It was also noted in this study that weak CD4 T cell and neutralizing antibody responses were generated by DNA alone. To broaden the type of immune responses, a DNA prime/protein boost strategy was used in seronegative macaques, consisting of four DNA immunizations against pp65-2, gB, and immediate-early 1 (IE1), followed by two boosts with formalin-inactivated RhCMV virions. This heterologous prime/boost strategy elicited robust antigen-specific CD4 and CD8 T cell responses in addition to biologically relevant neutralizing antibody titers. Animals were challenged with RhCMV delivered into four sites via a subcutaneous route. Skin biopsies of one of the inoculation sites 7 days post challenge revealed marked differences in the level of RhCMV replication between the vaccinated and control monkeys. Whereas the inoculation site in the controls was noted for a prominent inflammatory response and numerous cytomegalic, antigen-positive (IE1) cells, the inoculation site in the vaccinees was characterized by an absence of inflammation and antigen-positive cells. All five vaccinees developed robust recall responses to viral antigens, and four of them exhibited long-term viral immune responses consistent with effective control of viral expression and replication. These results demonstrate that a heterologous DNA prime/protein boost strategy greatly expands the breadth of antiviral immune responses and greatly reduces the level of viral replication at the primary site of challenge infection.

show abstract

“…lang=en) in pigs. Aucouturier et al (2000) reported that antibodies were highly induced in BALB/c mice immunized with the combination of vaccine and Montanide Ò IMS adjuvants containing M1113, and the BALB/c mouse model can be useful in the initial selection of a combination of vaccine and this adjuvant (Aucouturier et al 2000). To optimize immunization with the ghost, we investigated immune responses against the K88 antigens after IM or oral inoculation with various combinations of the ghost and the adjuvants LTB and MI1113.…”

Section: Discussionmentioning

confidence: 99%

“…Inactivated vaccines, which include killed bacteria and isolated non-replicating components, stimulate a lower level and shorter duration of immunity than live vaccines (Marciani 2003). Thus, powerful adjuvants, including the B subunit of Escherichia coli heat-labile enterotoxin (LTB) (Moyle et al 2004) and chemical adjuvants such as MONTANIDE IMS 1113 (MI1113) (Aucouturier et al 2000), are used to increase immunity.…”

Section: Introductionmentioning

confidence: 99%

Salmonellaghosts expressing enterotoxigenicEscherichia colik88ab, k88ac, k99, and fasa fimbrial antigens induce robust immune responses in a mouse model

Hur

Kim

et al. 2015

Veterinary Quarterly

View full text Add to dashboard Cite

Results: All groups with single, double, and triple inoculations of the ghost showed higher humoral and mucosal immune responses than the control group. In particular, the groups with intramuscular double and triple inoculations showed significantly higher immune responses. In addition, oral inoculation with a combination of the ghost and MONTANIDE IMS 1113 (MI1113) resulted in high and prolonged induction of intestinal IgA levels. Conclusion: These results indicated that both systemic and mucosal immunity against ETEC fimbrial antigens expressed by the ghost are induced by intramuscular booster inoculation with the ghost, and that addition of M1113 to the ghost was found to result in prominent induction of mucosal immunity through oral inoculation.

show abstract

Efficacy and Safety of New Adjuvants

Cited by 22 publications

References 2 publications

Generation of Humoral Immune Responses to Multi-Allele PfAMA1 Vaccines; Effect of Adjuvant and Number of Component Alleles on the Breadth of Response

Generation of Humoral Immune Responses to Multi-Allele PfAMA1 Vaccines; Effect of Adjuvant and Number of Component Alleles on the Breadth of Response

A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus

Salmonellaghosts expressing enterotoxigenicEscherichia colik88ab, k88ac, k99, and fasa fimbrial antigens induce robust immune responses in a mouse model

Contact Info

Product

Resources

About